Truist has increased its price target for Glaukos to $255 from $215, while reiterating a Buy rating, following strong Q3 2026 earnings that surpassed analyst expectations. This positive revision reflects the company's robust financial performance and suggests continued confidence from the analyst community.
Truist's decision to raise Glaukos's price target to $255 from $215, while maintaining a Buy rating, stems directly from the company's impressive Q3 2026 earnings. Glaukos significantly outperformed FactSet consensus estimates with $211.0 million in revenue and $0.47 adjusted EPS. This positive analyst action indicates strong confidence in Glaukos's financial trajectory and operational execution, likely leading to short-term positive sentiment and potential upward movement in the stock. For traders, this signals a potential buying opportunity, reinforcing the long-term growth prospects of the company within the healthcare sector.